Is Intuitive Surgical Stock a Buy?
Generated by AI AgentMarcus Lee
Wednesday, Mar 26, 2025 9:47 pm ET1min read
ISRG--
In the ever-evolving landscape of medical technology, Intuitive SurgicalISRG-- (ISRG) stands as a titan, pioneering robotic-assisted surgery with its da Vinci systems. But is the stock a buy? Let's dive deep into the numbers, the hype, and the realities to find out.
The Bull Case: Growth and Dominance
Intuitive Surgical's Q4 2024 earnings report was a blockbuster. Revenue soared 25% year-over-year to $2.41 billion, driven by an 18% increase in da Vinci procedures and 493 system placements. The company's installed base grew 15% to nearly 9,900 systems, a testament to its market dominance.
The growth story doesn't stop there. Intuitive Surgical is forecast to grow earnings and revenue by 12.8% and 12% per annum respectively, with EPS expected to grow by 12.5% per annum. The company's return on equity is projected to be 14.8% in three years, indicating strong profitability.
The Bear Case: Valuation and Competition
Despite the impressive growth, there are reasons to be cautious. Intuitive Surgical's stock has fallen by -17.93% in the past month, partly due to the da Vinci 5 recall and increased competition. The recall, initiated in February 2025, could lead to a decrease in procedure volumes and increased expenses, pressuring the company's operating margins.
Moreover, the company's expected non-GAAP gross profit margin for 2025 is forecasted to decline to 67%-68%, down from 69.1% in 2024. This, coupled with potential risks from new tariffs, suggests vulnerability to external economic factors.
The Verdict: Proceed with Caution
Intuitive Surgical's strong revenue growth, growing installed base, and positive earnings growth make a compelling case for investment. However, the potential slowdown in procedure growth, declining gross profit margins, and recent stock price decline present challenges.
Investors should carefully consider these factors and keep an eye on the da Vinci 5 recall resolution. If the company can navigate these challenges successfully, Intuitive Surgical could continue to be a strong performer. But for now, it might be wise to proceed with caution.
In the ever-evolving landscape of medical technology, Intuitive SurgicalISRG-- (ISRG) stands as a titan, pioneering robotic-assisted surgery with its da Vinci systems. But is the stock a buy? Let's dive deep into the numbers, the hype, and the realities to find out.
The Bull Case: Growth and Dominance
Intuitive Surgical's Q4 2024 earnings report was a blockbuster. Revenue soared 25% year-over-year to $2.41 billion, driven by an 18% increase in da Vinci procedures and 493 system placements. The company's installed base grew 15% to nearly 9,900 systems, a testament to its market dominance.
The growth story doesn't stop there. Intuitive Surgical is forecast to grow earnings and revenue by 12.8% and 12% per annum respectively, with EPS expected to grow by 12.5% per annum. The company's return on equity is projected to be 14.8% in three years, indicating strong profitability.
The Bear Case: Valuation and Competition
Despite the impressive growth, there are reasons to be cautious. Intuitive Surgical's stock has fallen by -17.93% in the past month, partly due to the da Vinci 5 recall and increased competition. The recall, initiated in February 2025, could lead to a decrease in procedure volumes and increased expenses, pressuring the company's operating margins.
Moreover, the company's expected non-GAAP gross profit margin for 2025 is forecasted to decline to 67%-68%, down from 69.1% in 2024. This, coupled with potential risks from new tariffs, suggests vulnerability to external economic factors.
The Verdict: Proceed with Caution
Intuitive Surgical's strong revenue growth, growing installed base, and positive earnings growth make a compelling case for investment. However, the potential slowdown in procedure growth, declining gross profit margins, and recent stock price decline present challenges.
Investors should carefully consider these factors and keep an eye on the da Vinci 5 recall resolution. If the company can navigate these challenges successfully, Intuitive Surgical could continue to be a strong performer. But for now, it might be wise to proceed with caution.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet